Guidance+1
Current guidance was classified as raised.
Low confidenceEarnings thesis change · rubric v1.0
ZTS Zoetis Inc.
Fiscal Q3 FY2026 · quarter ended September 30, 2026 · reported 2026-11-05
SEC filings and exhibits only
Earnings filing (8-K) · Latest 10-Q filings
Last updated: Nov 5, 2026 at 9:33 PM UTC
Earnings filing (8-K) · Latest 10-Q filings
Last updated: Nov 5, 2026 at 9:33 PM UTC
ACCOUNTING RISK · CLEAR
No auditor changes, restatements, late filings, or listing notices in the last 12 months.
from SEC filings · 2026-10-09
Thesis change
Strengthened
Legacy analysis
Legacy analysis: only the dimensions classifiable by the pre-v1 pipeline are shown.
- Legacy analysis: scored by the pre-v1 pipeline; deep evidence has not been re-verified.
- 5 thesis dimension(s) lack comparable evidence
Reported facts
GAAP facts are reported by the company. Comparable figures are EarnIQ arithmetic using only quantified adjustments disclosed in the linked SEC exhibit.
Earnings quality
From 10-Q / 10-K XBRL filings. Sloan (1996) accruals: high accruals relative to assets have historically preceded earnings disappointments. Descriptive research, not a prediction.
Weak — accruals are doing the heavy lifting
Reported profits have been driven more by accounting accruals than cash. Latest quarter: accruals equal -0.9% of assets — in the weakest quintile of large caps.
CY2024Q3Accruals / assets (TTM)CY2026Q2
Depreciation is disclosed annually by most filers, so quarterly values blend actuals with estimates — flagged on every reading. Method: TTM Sloan accruals ÷ average assets, scored 1–5 by quintile.
1. Three decisive changes
Largest quantified changes versus the company's own history.
+14.8%
Net income — year over year
$691.0M vs $602.0M a year ago · quarter ended Jun 30, 2026 · from 10-Q XBRL filings.
+12.3%
Revenue — year over year
$2.5B vs $2.2B a year ago · quarter ended Jun 30, 2026 · from 10-Q XBRL filings.
2. Was it already expected?
Consensus classifications require timestamped pre-report snapshots and eight-quarter surprise history.
| Item | Actual | Expected | Gap | Class |
|---|---|---|---|---|
| Consensus comparison coming soon. | ||||
3. Management consistency
Only attributable, measurable and dated commitments are counted. Delivery record: 1 being tracked.
| Promise | Target | Outcome | Status | Evidence |
|---|---|---|---|---|
| Convenia RTU for Dogs is expected to be available to veterinarians in the first quarter of 2027.other · made 2026-11-05 | available to veterinariansQ1 2027 | — | Pending | 8-K 0001555280-26-0000 |
4. What matters next
One deciding measurable condition plus up to two supporting checkpoints.
The deciding condition
EPS for the guided period lands within $6.25–$6.35
StrengthensReported EPS above $6.35
InvalidatesReported EPS below $6.25
Revenue within $9.22B–$9.32B
Strengthens: Revenue above $9.32BWeakens: Revenue below $9.22BNarrowed full year 2026 revenue guidance to $9.220B-$9.320B and raised adjusted diluted EPS guidance to $6.25-$6.35.
5. Risks that changed
New or materially worsened items only; unchanged boilerplate is omitted.
No new or materially worsened risk has been source-verified.
From 10-K filings · EDGAR
9
new risk disclosures added
8
old ones removed
FY2025 10-K vs prior year, boilerplate filtered out — these are idiosyncratic changes, and tone is slightly less negative.
New risk disclosure #1
“• the outbreak of any highly contagious diseases at or near our production sites. These interruptions could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with our agreements under w…”
New risk disclosure #2
“Item 1A. Risk Factors. In addition to the other information set forth in this 2025 Annual Report, any of the factors described below could materially adversely affect our operating results, financial condition and liquid…”
New risk disclosure #3
“are increasing in their frequency, sophistication and intensity, including through the use of AI and have become increasingly difficult to detect; and could include wrongful conduct by hostile foreign governments, indust…”
6. Evidence drawer
Source location, short anchor and visible arithmetic for every verified claim.
DC1 10-Q / 10-K XBRL filings (US-GAAP, via EDGAR)
Net income · quarter ended 2026-06-30Net income: +14.8% year over year
(691,000,000 − 602,000,000) ÷ 602,000,000 = +14.8% YoYDC2 10-Q / 10-K XBRL filings (US-GAAP, via EDGAR)
Revenue · quarter ended 2026-06-30Revenue: +12.3% year over year
(2,468,000,000 − 2,198,000,000) ÷ 2,198,000,000 = +12.3% YoYWN1 8-K Exhibit 99.1 (earnings release, via EDGAR)
Guidance disclosed for Q3 FY2026EPS for the guided period lands within $6.25–$6.35
Strengthens: Reported EPS above $6.35 · Invalidates: Reported EPS below $6.25